About Pinteon Therapeutics

About company

Pinteon Therapeutics focuses on the discovery and development of breakthrough therapeutics targeting Pin1. Pin1 acts as a central regulator in cancer development and growth as well as a number of other disease areas including CNS and autoimmune diseases. By inhibiting or activating Pin1, Pinteon will normalize aberrant disease processes and improve patient outcomes in these high unmet medical need indications. Pinteon Therapeutics was founded in 2014 and is headquartered in Newton, Massachusetts.